Thetis Pharma is a privately-held biopharmaceutical brand focused on developing Resolvin-based therapies for inflammatory diseases. Their mission is to make Resolvins druggable in order to control inflammation resolution effectively. Resolvins are endogenous lipids that actively coordinate the resolution of inflamed tissue, unlike traditional anti-inflammatory drugs that inhibit immune function.

Thetis is currently developing TP-317, a groundbreaking Resolvin E1 small molecule drug, specifically targeting inflammatory bowel disease such as ulcerative colitis and Crohn’s disease, as well as gastrointestinal cancers. With a combined addressable market value of $50+ billion, these diseases have significant unmet needs. Thetis is backed by venture capital investors, NIH, and top private philanthropies, including the Helmsley Charitable Trust, the Crohn’s & Colitis Foundation, and the Kenneth Rainin Foundation.

Located in Ridgefield, CT, Thetis Pharmaceuticals is committed to pioneering innovative solutions in the field of inflammatory diseases